FDA views on the use of R and other nonproprietary software [Software]
I stumbled upon this presentation by chance.
The future looks bright for R.
A good weekend to all of you.
if (3) 4
"(...) targeted cancer therapies will benefit fewer than 2 percent of the cancer patients they’re aimed at. That reality is often lost on consumers, who are being fed a steady diet of winning anecdotes about miracle cures." New York Times (ed.), June 9, 2018.